Zydus Cadila has signed a strategic collaboration agreement with Eczactbast hag Pazarlama A.S., a leading healthcare company of Turkey to market biotech products in the Turkish market. The agreement involves the import of biosimilars which are currently unavailable in the country especially for the treatment of cancer and it also paves the way for a long term strategic collaboration to produce and launch new products in the market.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.
